(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
Justin Gover, CEO of GW Pharmaceuticals, on the drug pipeline for the UK- based company which has been developing drug treatments derived from cannabis for decades.

<p>(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
Justin Gover, CEO of GW Pharmaceuticals, on the drug pipeline for the UK- based company which has been developing drug treatments derived from cannabis for decades.</p>

Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

<p>Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.</p>

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze markets, companies and industries.

Bloomberg Intelligence

GW’s Gover on Cannabis-Derived Drug for Rare Epilepsy (Audio)

GW's Gover on Cannabis-Derived Drug for Rare Epilepsy (Audio)

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/5d7081c7-6221-43a1-a66d-ae3c00a1cbfc/transcript

Advertisement